Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial

Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial

Objective: To assess the efficacy and safety of favipiravir in adults with mild-to-moderate coronavirus disease 2019 (COVID-19). Methods: In this randomized, open-label, parallel-arm, multicenter, phase 3 trial, adults (18–75 years) with RT-PCR confirmed COVID-19 and mild-to-moderate symptoms (inclu...

Full description

Bibliographic Details
Main Authors: Zarir F. Udwadia, Pawan Singh, Hanmant Barkate, Saiprasad Patil, Shabbir Rangwala, Amol Pendse, Jatin Kadam, Wen Wu, Cynthia F. Caracta, Monika Tandon
Format: Article
Language:English
Published: Elsevier 2021-02-01
Series:International Journal of Infectious Diseases
Subjects:
Favipiravir
SARS-CoV-2
COVID-19
Coronavirus
Antiviral
Randomized clinical trial
Online Access:http://www.sciencedirect.com/science/article/pii/S120197122032453X

Internet

http://www.sciencedirect.com/science/article/pii/S120197122032453X

Similar Items